|
|
總筆數:33
| 篇名 | 作者 | 刊名 | 出版年 | 查看 |
|---|
| The role of neurohormonal activation in chronic heart failure andpostmyocardial infarction |
Sigurdsson, A.;Swedberg, K.; |
American Heart Journal |
1996-07-01 |
查看 |
| The role of neurohormonal activation in chronic heart failure andpostmyocardial infarction |
Sigurdsson, A.;Swedberg, K.; |
American Heart Journal |
1996-07-01 |
查看 |
| The role of neurohormonal activation in chronic heart failure andpostmyocardial infarction |
Sigurdsson, A.;Swedberg, K.; |
American Heart Journal |
1996-07-01 |
查看 |
| The role of neurohormonal activation in chronic heart failure andpostmyocardial infarction |
Sigurdsson, A.;Swedberg, K.; |
American Heart Journal |
1996-07-01 |
查看 |
| A randomized controlled trial of epoprostenol therapy for severecongestive heart failure: The Flolan International Randomized SurvivalTrial (FIRST) |
Califf, R.M.;Adams, K.F.;McKenna, W.J.;Gheorghiade, M.;Uretsky, B.F.;McNulty, S.E.;Darius, H.;Schulman, K.;Zannad, F.;Handberg-Thurmond, E.;Harrell, F.E.;Wheeler, W.;Soler-Soler, J.;Swedberg, K.; |
American Heart Journal |
1997-07-01 |
查看 |
| A randomized controlled trial of epoprostenol therapy for severecongestive heart failure: The Flolan International Randomized SurvivalTrial (FIRST) |
Califf, R.M.;Adams, K.F.;McKenna, W.J.;Gheorghiade, M.;Uretsky, B.F.;McNulty, S.E.;Darius, H.;Schulman, K.;Zannad, F.;Handberg-Thurmond, E.;Harrell, F.E.;Wheeler, W.;Soler-Soler, J.;Swedberg, K.; |
American Heart Journal |
1997-07-01 |
查看 |
| Current and novel pharmacologic approaches in advanced heart failure |
O'Connor, C.M.;Gattis, W.A.;Swedberg, K.; |
American Heart Journal |
1998-06-01 |
查看 |
| Is 6-minute walk test of value in congestive heart failure? |
Schaufelberger, M.;Swedberg, K.; |
American Heart Journal |
1998-09-01 |
查看 |
| Is 6-minute walk test of value in congestive heart failure? |
Schaufelberger, M.;Swedberg, K.; |
American Heart Journal |
1998-09-01 |
查看 |
| Continuous intravenous dobutamine is associated with an increased riskof death in patients with advanced heart failure: Insights from the FlolanInternational Randomized Survival Trial (FIRST) |
For the FIRST Investigators;O'Connor, C.M.;Gattis, W.A.;Uretsky, B.F.;Adams, K.F.;McNulty, S.E.;Grossman, S.H.;McKenna, W.J.;Zannad, F.;Swedberg, K.;Gheorghiade, M.;Califf, R.M.; |
American Heart Journal |
1999-07-01 |
查看 |
| Continuous intravenous dobutamine is associated with an increased riskof death in patients with advanced heart failure: Insights from the FlolanInternational Randomized Survival Trial (FIRST) |
For the FIRST Investigators;O'Connor, C.M.;Gattis, W.A.;Uretsky, B.F.;Adams, K.F.;McNulty, S.E.;Grossman, S.H.;McKenna, W.J.;Zannad, F.;Swedberg, K.;Gheorghiade, M.;Califf, R.M.; |
American Heart Journal |
1999-07-01 |
查看 |
| Randomized trial of candesartan cilexetil in the treatment of patients withcongestive heart failure and a history of intolerance toangiotensin-converting enzyme inhibitors |
Granger, C.B.;Ertl, G.;Kuch, J.;Maggioni, A.P.;McMurray, J.;Rouleau, J.-L.;Warner Stevenson, L.;Swedberg, K.;Young, J.;Yusuf, S.;Califf, R.M.;Bart, B.A.;Held, P.;Michelson, E.L.;Sellers, M.A.;Ohlin, G.;Sparapani, R.;Pfeffer, M.A.;Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE);Investigators; |
American Heart Journal |
2000-04-01 |
查看 |
| Prognostic importance of the oxidized product of catecholamines,adrenolutin, in patients with severe heart failure |
Rouleau, J.L.;Pitt, B.;Dhalla, N.S.;Dhalla, K.S.;Swedberg, K.;Hansen, M.S.;Stanton, E.;Lapointe, N.;Packer, M.;Canadian Prospective RandOmized FlosequInan Longevity Evaluation (PROFILE);Investigators; |
American Heart Journal |
2003-05-01 |
查看 |
| Prognostic importance of the oxidized product of catecholamines,adrenolutin, in patients with severe heart failure |
Rouleau, J.L.;Pitt, B.;Dhalla, N.S.;Dhalla, K.S.;Swedberg, K.;Hansen, M.S.;Stanton, E.;Lapointe, N.;Packer, M.;Canadian Prospective RandOmized FlosequInan Longevity Evaluation (PROFILE);Investigators; |
American Heart Journal |
2003-05-01 |
查看 |
| Effects of metoprolol and carvedilol on cause-specific mortality andmorbidity in patients with chronic heart failure-COMET |
Torp-Pedersen, C.;Poole-Wilson, P.A.;Swedberg, K.;Cleland, J.G.F.;Di Lenarda, A.;Hanrath, P.;Komajda, M.;Lutiger, B.;Metra, M.;Remme, W.J.;Scherhag, A.;Skene, A.;for the COMET Investigators; |
American Heart Journal |
2005-02-01 |
查看 |
| Effects of metoprolol and carvedilol on cause-specific mortality andmorbidity in patients with chronic heart failure-COMET |
Torp-Pedersen, C.;Poole-Wilson, P.A.;Swedberg, K.;Cleland, J.G.F.;Di Lenarda, A.;Hanrath, P.;Komajda, M.;Lutiger, B.;Metra, M.;Remme, W.J.;Scherhag, A.;Skene, A.;for the COMET Investigators; |
American Heart Journal |
2005-02-01 |
查看 |
| Effects of metoprolol and carvedilol on cause-specific mortality andmorbidity in patients with chronic heart failure-COMET |
Torp-Pedersen, C.;Poole-Wilson, P.A.;Swedberg, K.;Cleland, J.G.F.;Di Lenarda, A.;Hanrath, P.;Komajda, M.;Lutiger, B.;Metra, M.;Remme, W.J.;Scherhag, A.;Skene, A.;for the COMET Investigators; |
American Heart Journal |
2005-02-01 |
查看 |
| Effects of metoprolol and carvedilol on cause-specific mortality andmorbidity in patients with chronic heart failure-COMET |
for the COMET Investigators;Torp-Pedersen, C.;Poole-Wilson, P.A.;Swedberg, K.;Cleland, J.G.F.;Di Lenarda, A.;Hanrath, P.;Komajda, M.;Lutiger, B.;Metra, M.;Remme, W.J.;Scherhag, A.;Skene, A.; |
American Heart Journal |
2005-02-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Yusuf, S.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Relationship of dose of background angiotensin-converting enzymeinhibitor to the benefits of candesartan in the Candesartan in Heartfailure: Assessment of Reduction in Mortality and morbidity (CHARM)-Addedtrial |
on behalf of the CHARM Investigators;McMurray, J.J.V.;Young, J.B.;Dunlap, M.E.;Granger, C.B.;Hainer, J.;Michelson, E.L.;Earle, S.;Olofsson, B.;Ostergren, J.;Yusuf, S.;Swedberg, K.;Pfeffer, M.A.; |
American Heart Journal |
2006-05-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
on behalf of the CHARM Investigators;Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Olofsson, B.;Puu, M.;Yusuf, S.; |
American Heart Journal |
2006-07-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
on behalf of the CHARM Investigators;Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Olofsson, B.;Puu, M.;Yusuf, S.; |
American Heart Journal |
2006-07-01 |
查看 |
| Prevention of atrial fibrillation in patients with symptomatic chronicheart failure by candesartan in the Candesartan in Heart failure:Assessment of Reduction in Mortality and morbidity (CHARM) program |
on behalf of the CHARM Investigators;Ducharme, A.;Swedberg, K.;Pfeffer, M.A.;Cohen-Solal, A.;Granger, C.B.;Maggioni, A.P.;Michelson, E.L.;McMurray, J.J.V.;Olsson, L.;Rouleau, J.L.;Young, J.B.;Olofsson, B.;Puu, M.;Yusuf, S.; |
American Heart Journal |
2006-07-01 |
查看 |
| Fatal myocardial rupture after acute myocardial infarction complicatedby heart failure, left ventricular dysfunction, or both: The VALsartan InAcute myocardial iNfarcTion Trial (VALIANT) |
for the VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial;Investigators;Shamshad, F.;Kenchaiah, S.;Finn, P.V.;Soler-Soler, J.;McMurray, J.J.V.;Velazquez, E.J.;Maggioni, A.P.;Califf, R.M.;Swedberg, K.;Kober, L.;Belenkov, Y.;Varshavsky, S.;Pfeffer, M.A.;Solomon, S.D.; |
American Heart Journal |
2010-07-01 |
查看 |
| Effects of tolvaptan on physician-assessed symptoms and signs inpatients hospitalized with acute heart failure syndromes: Analysis from theEfficacy of Vasopressin Antagonism in Heart Failure Outcome Study withTolvaptan (EVEREST) Trials |
Pang, P.S.;Gheorghiade, M.;Dihu, J.;Swedberg, K.;Khan, S.;Maggioni, A.P.;Grinfeld, L.;Zannad, F.;Burnett, J.C.;Ouyang, J.;Udelson, J.E.;Konstam, M.A.; |
American Heart Journal |
2011-06-01 |
查看 |
| Days alive and out of hospital and the patient journey in patients withheart failure: Insights from the Candesartan in Heart failure: Assessmentof Reduction in Mortality and morbidity (CHARM) program |
Ariti, C.A.;Cleland, J.G.F.;Pocock, S.J.;Pfeffer, M.A.;Swedberg, K.;Granger, C.B.;McMurray, J.J.V.;Michelson, E.L.;Ostergren, J.;Yusuf, S.; |
American Heart Journal |
2011-11-01 |
查看 |
| Days alive and out of hospital and the patient journey in patients withheart failure: Insights from the Candesartan in Heart failure: Assessmentof Reduction in Mortality and morbidity (CHARM) program |
Ariti, C.A.;Cleland, J.G.F.;Pocock, S.J.;Pfeffer, M.A.;Swedberg, K.;Granger, C.B.;McMurray, J.J.V.;Michelson, E.L.;Ostergren, J.;Yusuf, S.; |
American Heart Journal |
2011-11-01 |
查看 |
| Atrial fibrillation or flutter on initial electrocardiogram isassociated with worse outcomes in patients admitted for worsening heartfailure with reduced ejection fraction: Findings from the EVEREST Trial |
Mentz, R.J.;Chung, M.J.;Gheorghiade, M.;Pang, P.S.;Kwasny, M.J.;Ambrosy, A.P.;Vaduganathan, M.;O'Connor, C.M.;Swedberg, K.;Zannad, F.;Konstam, M.A.;Maggioni, A.P.; |
American Heart Journal |
2012-12-01 |
查看 |
| Clinical profile and prognostic value of low systolic blood pressure inpatients hospitalized for heart failure with reduced ejection fraction:Insights from the Efficacy of Vasopressin Antagonism in Heart Failure:Outcome Study with Tolvaptan (EVEREST) trial |
Ambrosy, A.P.;Vaduganathan, M.;Mentz, R.J.;Greene, S.J.;Subacius, H.;Konstam, M.A.;Maggioni, A.P.;Swedberg, K.;Gheorghiade, M.; |
American Heart Journal |
2013-02-01 |
查看 |
|
|
|
